Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Inclusion Criteria: * Age \>= 18 years * Female * Resected unilateral or bilateral primary carcinoma of the breast without clinical evidence of metastatic disease (after neoadjuvant chemotherapy and/or adjuvant chemotherapy), negative for estrogen receptor (ER) and progesterone receptor (PR) (cut-off for positivity is \> 10% positive tumor cells with nuclear staining), and negative for HER2 as defined by one of the four situations delineated below: * HER2 immunohistochemistry (IHC) expression of 0 or 1+ and in-situ hybridization non-amplified * HER2 IHC expression of 0 or 1+ and in-situ hybridization not done * HER2 IHC expression of 2+ and in-situ hybridization non-amplified * IHC not done and in-situ hybridization non-amplified * Note: central review is not required * Note: If biopsy and surgical specimens are discordant from each other with regard to ER, PR, and/or HER2 status, a patient will be allowed to enroll assuming at least one of the specimens meets the above criteria and no endocrine therapy use is planned going forward * Completed planned breast CANCER surgeries, any radiation therapy, and any chemotherapy, whichever is last, \>= 90 days but not \>= 546 days prior to randomization * Note: Reconstructive and prophylactic surgeries are allowed after randomization (during study treatment) * Patient had at least one of the following: * Biopsy or surgery-proven regional node involvement by cancer * T1c, T2, T3, or T4 disease (with inflammatory di…